{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:09:36Z","timestamp":1786684176739,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Odense University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, there are no reliable biomarkers for predicting treatment response in chronic inflammatory diseases (CIDs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To determine whether serum microfibrillar-associated protein 4 (MFAP4) levels can predict the treatment response to biological therapy in patients with CIDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The BELIEVE study was originally designed as a prospective, multi-center cohort study of 233 patients with either rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, Crohn\u2019s disease, or ulcerative colitis, initiating treatment with a biologic agent (or switching to another). Clinical assessment and blood sample collection were performed at baseline and 14\u201316 weeks after treatment initiation. The primary analyses included participants with available blood samples at baseline; missing data were handled as non-responders. The patients were stratified into the upper tertile of serum MFAP4 (High MFAP4) versus a combined category of middle and lower tertiles (Other MFAP4). The primary outcome was the proportion of patients with clinical response to biologic therapy after 14\u201316 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>211 patients were included in the primary analysis population. The mean age was 43.7 (SD: 14.8) years, and 120 (59%) were female. Positive treatment response was observed in 41 (59%) and 69 (49%) for High MFAP4 and Other MFAP4, respectively. When adjusting for pre-specified variables (CID, age, sex, smoking status, and BMI), the adjusted OR was 2.28 (95% CI: 1.07 to 4.85) for a positive treatment outcome in the High MFAP4 group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A high MFAP4 status before initiating biological treatment is associated with a positive clinical response, when adjusting for confounding factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00296-024-05744-9","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:41:13Z","timestamp":1730104873000},"page":"2935-2947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5918-3206","authenticated-orcid":false,"given":"Bj\u00f8rk K.","family":"Sof\u00edud\u00f3ttir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-6283","authenticated-orcid":false,"given":"Heidi L.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6600-0631","authenticated-orcid":false,"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-4269","authenticated-orcid":false,"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-2154","authenticated-orcid":false,"given":"Silja H.","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-1097","authenticated-orcid":false,"given":"Grith L.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-0474","authenticated-orcid":false,"given":"Karen M.","family":"M\u00f8llegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-094X","authenticated-orcid":false,"given":"Jessica","family":"Pingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-9748","authenticated-orcid":false,"given":"Anders B.","family":"Nex\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-8766","authenticated-orcid":false,"given":"Henning","family":"Glerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Guldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-7636","authenticated-orcid":false,"given":"Jens Frederik","family":"Dahlerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-7184","authenticated-orcid":false,"given":"Christian L.","family":"Hvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina W.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-2548","authenticated-orcid":false,"given":"Mohamad","family":"Jawhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4612-8635","authenticated-orcid":false,"given":"Ole Haagen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6321-7715","authenticated-orcid":false,"given":"Fredrik Olof","family":"Bergenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3004-0180","authenticated-orcid":false,"given":"Anette","family":"Bygum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-4014","authenticated-orcid":false,"given":"Jesper R.","family":"Davidsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-1236","authenticated-orcid":false,"given":"Signe Bek","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-7554","authenticated-orcid":false,"given":"Jacob B.","family":"Brodersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-6572","authenticated-orcid":false,"given":"Jens","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-2863","authenticated-orcid":false,"given":"Vibeke","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-4962","authenticated-orcid":false,"given":"Torkell","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"10114","key":"5744_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London England) 390(10114):2769\u20132778","journal-title":"Lancet (London England)"},{"issue":"4","key":"5744_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41(4):545\u2013568","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"5744_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316\u20131322","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5744_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A (2018) Quality of life in inflammatory bowel disease: a systematic review and Meta-analyses-part I. Inflamm Bowel Dis 24(4):742\u2013751","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"5744_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76(10):1700\u20131706","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5744_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/pgs.13.60","volume":"14","author":"I Acosta-Colman","year":"2013","unstructured":"Acosta-Colman I, Palau N, Tornero J et al (2013) GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14(7):727\u2013734","journal-title":"Pharmacogenomics"},{"issue":"29","key":"5744_CR7","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2174\/138161211798157658","volume":"17","author":"J Geiler","year":"2011","unstructured":"Geiler J, Buch M, McDermott MF (2011) Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 17(29):3141\u20133154","journal-title":"Curr Pharm Des"},{"issue":"7","key":"5744_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/MEG.0b013e328331b654","volume":"22","author":"V Leso","year":"2010","unstructured":"Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G (2010) Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 22(7):779\u2013786","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5744_CR9","doi-asserted-by":"crossref","unstructured":"Andersen V, Holmskov U, Sorensen SB et al (2017) A proposal for a study on Treatment Selection and Lifestyle recommendations in Chronic Inflammatory diseases: a Danish multidisciplinary collaboration on prognostic factors and Personalised Medicine. Nutrients 9 (5)","DOI":"10.3390\/nu9050499"},{"key":"5744_CR10","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011 (2):Cd008794","DOI":"10.1002\/14651858.CD008794"},{"issue":"9317","key":"5744_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet (London England) 359(9317):1541\u20131549","journal-title":"Lancet (London England)"},{"issue":"13","key":"5744_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372","journal-title":"JAMA"},{"issue":"1","key":"5744_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","volume":"72","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Aletaha D (2013) Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 72(1):3\u20136","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5744_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41575-019-0228-5","volume":"17","author":"JL Digby-Bell","year":"2020","unstructured":"Digby-Bell JL, Atreya R, Monteleone G, Powell N (2020) Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17(1):9\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5744_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2022.05.008","volume":"111","author":"R Kanaan","year":"2022","unstructured":"Kanaan R, Medlej-Hashim M, Jounblat R, Pilecki B, Sorensen GL (2022) Microfibrillar-associated protein 4 in health and disease. Matrix Biol 111:1\u201325","journal-title":"Matrix Biol"},{"issue":"4","key":"5744_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/hep.22764","volume":"49","author":"C Molleken","year":"2009","unstructured":"Molleken C, Sitek B, Henkel C et al (2009) Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology (Baltimore MD) 49(4):1257\u20131266","journal-title":"Hepatology (Baltimore MD)"},{"issue":"10","key":"5744_CR17","doi-asserted-by":"publisher","first-page":"e0140418","DOI":"10.1371\/journal.pone.0140418","volume":"10","author":"SG S\u00e6kmose","year":"2015","unstructured":"S\u00e6kmose SG, M\u00f6ssner B, Christensen PB et al (2015) Microfibrillar-Associated protein 4: a potential biomarker for screening for liver fibrosis in a mixed patient cohort. PLoS ONE 10(10):e0140418","journal-title":"PLoS ONE"},{"issue":"1","key":"5744_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12967-016-0952-3","volume":"14","author":"T Bracht","year":"2016","unstructured":"Bracht T, M\u00f6lleken C, Ahrens M et al (2016) Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Translational Med 14(1):201","journal-title":"J Translational Med"},{"issue":"1","key":"5744_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-018-1523-6","volume":"16","author":"LE Hemstra","year":"2018","unstructured":"Hemstra LE, Schlosser A, Lindholt JS, Sorensen GL (2018) Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease. J Translational Med 16(1):159","journal-title":"J Translational Med"},{"issue":"3","key":"5744_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5114\/aoms.2018.74953","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang X, Li H, Kou W et al (2019) Increased plasma microfibrillar-associated protein 4 is associated with atrial fibrillation and more advanced left atrial remodelling. Arch Med Sci 15(3):632\u2013640","journal-title":"Arch Med Sci"},{"issue":"12","key":"5744_CR21","doi-asserted-by":"publisher","first-page":"e82383","DOI":"10.1371\/journal.pone.0082383","volume":"8","author":"SG Saekmose","year":"2013","unstructured":"Saekmose SG, Schlosser A, Holst R et al (2013) Enzyme-linked immunosorbent assay characterization of basal variation and heritability of systemic microfibrillar-associated protein 4. PLoS ONE 8(12):e82383","journal-title":"PLoS ONE"},{"issue":"12","key":"5744_CR22","doi-asserted-by":"publisher","first-page":"e82243","DOI":"10.1371\/journal.pone.0082243","volume":"8","author":"H Wulf-Johansson","year":"2013","unstructured":"Wulf-Johansson H, Lock Johansson S, Schlosser A et al (2013) Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. PLoS ONE 8(12):e82243","journal-title":"PLoS ONE"},{"issue":"11","key":"5744_CR23","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1096\/fj.202001026R","volume":"34","author":"Z Pan","year":"2020","unstructured":"Pan Z, Yang K, Wang H et al (2020) MFAP4 deficiency alleviates renal fibrosis through inhibition of NF-\u03baB and TGF-\u03b2\/Smad signaling pathways. Faseb j 34(11):14250\u201314263","journal-title":"Faseb j"},{"issue":"9","key":"5744_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/thoraxjnl-2014-206609","volume":"70","author":"B Pilecki","year":"2015","unstructured":"Pilecki B, Schlosser A, Wulf-Johansson H et al (2015) Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. Thorax 70(9):862\u2013872","journal-title":"Thorax"},{"key":"5744_CR25","doi-asserted-by":"publisher","first-page":"985732","DOI":"10.3389\/fnut.2022.985732","volume":"9","author":"SH Overgaard","year":"2022","unstructured":"Overgaard SH, S\u00f8rensen SB, Munk HL et al (2022) Impact of fibre and red\/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: a prospective cohort study. Front Nutr 9:985732","journal-title":"Front Nutr"},{"issue":"2","key":"5744_CR26","doi-asserted-by":"publisher","first-page":"e018166","DOI":"10.1136\/bmjopen-2017-018166","volume":"8","author":"R Christensen","year":"2018","unstructured":"Christensen R, Heitmann BL, Andersen KW et al (2018) Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. BMJ open 8(2):e018166","journal-title":"BMJ open"},{"issue":"10","key":"5744_CR27","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the reporting of Observational studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4(10):e297","journal-title":"PLoS Med"},{"issue":"6","key":"5744_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727\u2013735","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"5744_CR29","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl 2):ii1\u201344","journal-title":"Ann Rheum Dis"},{"key":"5744_CR30","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inf 95:103208","journal-title":"J Biomed Inf"},{"issue":"25","key":"5744_CR31","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083\u20133107","journal-title":"Stat Med"},{"key":"5744_CR32","doi-asserted-by":"crossref","unstructured":"Meccanici F, Thijssen CGE, Dekker S et al (2023) Circulating biomarkers associated with aortic diameter in male and female patients with thoracic aortic disease: a cross-sectional study. Open Heart 10 (1)","DOI":"10.1136\/openhrt-2023-002317"},{"issue":"3","key":"5744_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jgh3.12873","volume":"7","author":"R Kanaan","year":"2023","unstructured":"Kanaan R, Yaghi C, Saade Riachy C et al (2023) Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients. JGH Open 7(3):197\u2013203","journal-title":"JGH Open"},{"issue":"4","key":"5744_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00592-016-0953-y","volume":"54","author":"SL Blindbaek","year":"2017","unstructured":"Blindbaek SL, Schlosser A, Green A, Holmskov U, Sorensen GL, Grauslund J (2017) Association between microfibrillar-associated protein 4 (MFAP4) and micro- and macrovascular complications in long-term type 1 diabetes mellitus. Acta Diabetol 54(4):367\u2013372","journal-title":"Acta Diabetol"},{"issue":"7","key":"5744_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","volume":"43","author":"M Kosinski","year":"2000","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr (2000) Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43(7):1478\u20131487","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5744_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.rmed.2014.06.003","volume":"108","author":"SL Johansson","year":"2014","unstructured":"Johansson SL, Roberts NB, Schlosser A et al (2014) Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir Med 108(9):1336\u20131344","journal-title":"Respir Med"},{"issue":"1","key":"5744_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/thoraxjnl-2014-205091","volume":"70","author":"CA Brandsma","year":"2015","unstructured":"Brandsma CA, van den Berge M, Postma DS et al (2015) A large lung gene expression study identifying fibulin-5 as a novel player in tissue repair in COPD. Thorax 70(1):21\u201332","journal-title":"Thorax"},{"issue":"1","key":"5744_CR38","first-page":"122","volume":"38","author":"SF Issa","year":"2020","unstructured":"Issa SF, Lindegaard HM, Lorenzen T et al (2020) Increased serum levels of microfibrillar-associated protein 4 (MFAP4) are not associated with clinical synovitis in rheumatoid arthritis but may reflect underlying cardiovascular comorbidity. Clin Exp Rheumatol 38(1):122\u2013128","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"5744_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/iid3.254","volume":"7","author":"B Hoffmann-Petersen","year":"2019","unstructured":"Hoffmann-Petersen B, Suffolk R, Petersen JJH et al (2019) Microfibrillar-associated protein 4 in serum is associated with asthma in Danish adolescents and young adults. Immun Inflamm Dis 7(3):150\u2013159","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"5744_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13073-024-01356-x","volume":"16","author":"S Si","year":"2024","unstructured":"Si S, Liu H, Xu L, Zhan S (2024) Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome. Genome Med 16(1):84","journal-title":"Genome Med"},{"issue":"4","key":"5744_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000506827","volume":"10","author":"SP Kara","year":"2020","unstructured":"Kara SP, \u00d6zkan G, G\u00fcr D et al (2020) Relationship between Microfibrillar-Associated protein 4 levels and subclinical myocardial damage in chronic kidney disease. Cardiorenal Med 10(4):257\u2013265","journal-title":"Cardiorenal Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05744-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:06:38Z","timestamp":1733328398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5744"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05744-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is part of a PhD thesis, and some of the main findings of this study have been presented in the PhD thesis. The thesis can be accessed here: Bjork.K.Sofiudottir_rsyd.dk.pdf_reduced.pdf (sdu.dk).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors report no conflict of interest in relation to this study. BKS reports a congress-fee grant from Boehringer-Ingelheim, and JRD reports that he received teaching fees, congress-fee grants, and research grant from Boehringer-Ingelheim for another study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}